Akums demonstrates clinical versatility of Lacosamide in epilepsy care

Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.

AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month

Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness

Emcure and Dhoni, through a video, urge everyone to be aware about symptoms of stroke and educate at least one person for identification of stroke and spread its awareness

K J Somaiya Hospital & Research Centre launches advanced neurosciences centre in Mumbai

The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients

Aster Whitefield Hospital and government partner for free epilepsy camp in Kolar

The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024

Dr. Reddy's launches drug-free migraine management device Nerivio in Europe

Philips' direct-to-angio stroke pathway demonstrates improved patient outcomes

Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke pathway can save more than USD 3,000 per patient

Apollo Speciality Hospitals, Vanagaram organises vertigo awareness bicycle rally

The rally attracted around 250 riders, including professionals and amateurs.

Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS

Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022